US 12,251,424 B2
Methods of protecting vascular integrity induced by targeted radiation therapy
Gary Eichenbaum, Belle Mead, NJ (US); and Alfred Tonelli, Upper Nyack, NY (US)
Assigned to Janssen Pharmaceutica NV, Beerse (BE)
Appl. No. 16/633,854
Filed by Janssen Pharmaceutica NV, Beerse (BE)
PCT Filed Jul. 26, 2018, PCT No. PCT/US2018/043821
§ 371(c)(1), (2) Date Jan. 24, 2020,
PCT Pub. No. WO2019/023418, PCT Pub. Date Jan. 31, 2019.
Claims priority of provisional application 62/537,049, filed on Jul. 26, 2017.
Prior Publication US 2020/0164039 A1, May 28, 2020
Int. Cl. A61K 38/19 (2006.01); A61K 47/60 (2017.01); A61N 5/10 (2006.01)
CPC A61K 38/196 (2013.01) [A61K 47/60 (2017.08); A61N 5/10 (2013.01); A61N 2005/1094 (2013.01)] 21 Claims
 
1. A method of protecting vascular integrity in a subject exposed to a targeted radiation therapy, the method comprising administering to the subject an effective amount of a thrombopoietin (TPO) mimetic comprising the amino acid sequence of SEQ ID NO: 1, wherein the subject is exposed to the targeted radiation at a dose of 10-70 Gray (Gy), and further wherein the targeted radiation therapy is a therapy using ionizing radiation that is preferentially targeted or localized to a specific organ or part of the body.